Idioma:

Tenecteplase for Stroke at 4.5 to 24 Hours with Perfusion-Imaging Selection

Albers, Gregory W. ; Jumaa, Mouhammad ; Purdon, Barbara ; Zaidi, Syed F. ; Streib, Christopher ; Shuaib, Ashfaq ; Sangha, Navdeep ; Kim, Minjee ; Froehler, Michael T. ; Schwartz, Neil E. ; Clark, Wayne M. ; Kircher, Charles E. ; Yang, Ming ; Massaro, Lori ; Lu, Xiao-Yu ; Rippon, Gregory A. ; Broderick, Joseph P. ; Butcher, Ken ; Lansberg, Maarten G. ; Liebeskind, David S. ; Nouh, Amre ; Schwamm, Lee H. ; Campbell, Bruce C.V.

The New England journal of medicine, 2024-02, Vol.390 (8), p.701-711 [Periódico revisado por pares]

United States: Massachusetts Medical Society

Texto completo disponível

Citações Citado por

Enviar para

Título:
Tenecteplase for Stroke at 4.5 to 24 Hours with Perfusion-Imaging Selection
Autor: Albers, Gregory W. ; Jumaa, Mouhammad ; Purdon, Barbara ; Zaidi, Syed F. ; Streib, Christopher ; Shuaib, Ashfaq ; Sangha, Navdeep ; Kim, Minjee ; Froehler, Michael T. ; Schwartz, Neil E. ; Clark, Wayne M. ; Kircher, Charles E. ; Yang, Ming ; Massaro, Lori ; Lu, Xiao-Yu ; Rippon, Gregory A. ; Broderick, Joseph P. ; Butcher, Ken ; Lansberg, Maarten G. ; Liebeskind, David S. ; Nouh, Amre ; Schwamm, Lee H. ; Campbell, Bruce C.V.
Assuntos: Body weight ; Brain - blood supply ; Brain - diagnostic imaging ; Brain Ischemia - diagnostic imaging ; Brain Ischemia - drug therapy ; Brain Ischemia - mortality ; Brain Ischemia - surgery ; Cardiovascular system ; Carotid arteries ; Carotid artery ; Carotid Artery Diseases - diagnostic imaging ; Carotid Artery Diseases - drug therapy ; Carotid Artery Diseases - surgery ; Cerebral blood flow ; Clinical trials ; Design ; Double-Blind Method ; Emergency Medicine ; FDA approval ; Fibrinolytic Agents - administration & dosage ; Fibrinolytic Agents - adverse effects ; Fibrinolytic Agents - therapeutic use ; Hemorrhage ; Humans ; Infarction, Middle Cerebral Artery - diagnostic imaging ; Infarction, Middle Cerebral Artery - drug therapy ; Infarction, Middle Cerebral Artery - surgery ; Intracranial Hemorrhages - chemically induced ; Intracranial Hemorrhages - diagnostic imaging ; Ischemia ; Ischemic Stroke - diagnostic imaging ; Ischemic Stroke - drug therapy ; Ischemic Stroke - mortality ; Ischemic Stroke - surgery ; Magnetic resonance imaging ; Medical imaging ; Neurology ; Neurosurgery ; Patients ; Perfusion ; Perfusion Imaging - methods ; Placebos ; Stroke ; Stroke - diagnostic imaging ; Stroke - drug therapy ; Stroke - mortality ; Stroke - surgery ; Tenecteplase - administration & dosage ; Tenecteplase - adverse effects ; Tenecteplase - therapeutic use ; Thrombectomy - adverse effects ; Thrombectomy - methods ; Thrombolysis ; Time-to-Treatment ; Tissue Plasminogen Activator - administration & dosage ; Tissue Plasminogen Activator - adverse effects ; Tissue Plasminogen Activator - therapeutic use ; Treatment Outcome ; Veins & arteries
É parte de: The New England journal of medicine, 2024-02, Vol.390 (8), p.701-711
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
Descrição: Tenecteplase for thrombolysis in a 4.5-to-24-hour window did not improve disability outcomes at 90 days in patients with ischemic stroke who had been chosen on the basis of imaging. Most patients had endovascular thrombectomy.
Editor: United States: Massachusetts Medical Society
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Tenecteplase for Stroke at 4.5 to 24 Hours with Perfusion-Imaging Selection

United States: Massachusetts Medical Society

Buscando em bases de dados remotas. Favor aguardar.